Welcome to the
ALUNBRIG®
OnePath® Patient
Support Program
Website

ALUNBRIG® is used to treat adults with non-small cell lung cancer (NSCLC) that is caused by a change in the anaplastic lymphoma kinase (ALK) gene (called ALK-positive). These patients will have ALK-positive NSCLC that has grown outside of the lung (called locally advanced) or has spread to other parts of the body (called metastatic). A test is done to find out if there is a change in the ALK-gene.

For these patients, their disease:

  • cannot be cured with surgery or other treatment (like chemotherapy or radiation); and
  • will not have been previously treated.

ALUNBRIG® is also used in patients whose cancer has gotten worse after taking crizotinib or in patients who are unable to take crizotinib.

The OnePath® Patient Support Program is available to provide you with services and support throughout your treatment with ALUNBRIG®.

HERE ARE THE WAYS THAT OnePath® CAN ASSIST YOU:

Coordinating medication availability

Educating you about your medication

Assisting you in understanding your insurance coverage

Providing ongoing support

HELPFUL RESOURCES
Patient Brochure

Our patient brochure contains more information for you about treatment on ALUNBRIG®

Download
Lung Cancer Canada Website

The Lung Cancer Canada website has useful tools and tips that may be helpful for you

Click here
CONTACT US

We are here for you every step of your ALUNBRIG® treatment. If you have any questions, contact the OnePath® Patient Support Program toll‑free at:

Phone

1-844-MY1-PATH

(1-844-691-7284)
Fax

FAX

1-844-951-7284
Email

support@
onepathprogram.ca

Monday through Friday, 8 a.m. to 8 p.m. EST

Takeda Canada Inc. has contracted with an Administrator to provide the OnePath® Patient Support Program (the “Program”). Administrator independently runs and administers the Program and is Innomar Strategies Inc., located at 3470 Superior Court, Oakville, Ontario, Canada, L6L 0C4, and its affiliates or AmerisourceBergen Specialty Group Canada Inc., located at 4707 Levy, St-Laurent, Quebec, Canada, H4R 2P9, and its affiliates. I understand that the Administrator may change without notice. The Program is for the purpose of assisting patients who have been prescribed ALUNBRIG® (brigatinib). Program Personnel include the OnePath® Care Managers and employees and consultants of the Administrator.